I mean they could go alone, but it’s incredibly risky. The PRV would likely go for 80-100M USD which would cover their P2B EMA + Dual FDA preclin/clin trials, but likely would dry up and not cover the later phase 2 trials for the FDA. I doubt ANP management want to try and tackle these pipelines by themselves, but I could be wrong.0
Chart, page-4320
-
- There are more pages in this discussion • 1,586 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
